Lahmidani N, Hamdoun F Z, Lahlali M, Abid H, El Yousfi M, Benajah D A, El Abkari M, Ibrahimi S A
University Hospital Hassan II, School of Medicine and Pharmacy of Fez, Fez, Morocco.
University Sidi Mohammed Ben Abdallah, Morocco.
Gulf J Oncolog. 2020 May;1(33):64-67.
Alpha-fetoprotein (AFP) is a serum tumor marker used in the past for surveillance and screening of hepatocellular carcinoma (HCC) in patients with cirrhosis. Its prognostic value is still debated in the literature. The aim of this study was to evaluate the prognostic impact of the AFP rate at diagnosis on the overall survival of patients with a small HCC (<3cm) in patients with cirrhosis.
Among the 122 patients diagnosed with HCC during the study period, 49 patients had a small HCC at diagnosis, including 40,8% (N 20) patients with a negative AFP (group I) and 59,18% (N 29) with an AFP >10 ng / ml (group II). Both groups of patients were comparable for age and WHO status (World Health Organization). Patient survival was assessed by the Kaplan-Meier method. The survival at 5 years was 35.7% in group 1 vs 12.3% in group 2. The AFP level was identified as an independent prognostic factor of survival.
Alpha-fetoprotein serum positivity seems to have prognostic value in patients with single small HCC.
甲胎蛋白（AFP）是一种血清肿瘤标志物，过去用于肝硬化患者肝细胞癌（HCC）的监测和筛查。其预后价值在文献中仍存在争议。本研究的目的是评估诊断时AFP水平对肝硬化患者小肝癌（<3cm）患者总生存期的预后影响。
在研究期间诊断为HCC的122例患者中，49例患者诊断时患有小肝癌，其中40.8%（N=20）的患者AFP阴性（I组），59.18%（N=29）的患者AFP>10 ng/ml（II组）。两组患者在年龄和世界卫生组织（WHO）状态方面具有可比性。采用Kaplan-Meier法评估患者生存率。I组5年生存率为35.7%，II组为12.3%。AFP水平被确定为生存的独立预后因素。
甲胎蛋白血清阳性似乎对单个小肝癌患者具有预后价值。
